Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAP : NSDQ)
 
 • Company Description   
Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

Number of Employees: 494

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.64 Daily Weekly Monthly
20 Day Moving Average: 689,837 shares
Shares Outstanding: 161.87 (millions)
Market Capitalization: $265.46 (millions)
Beta: 2.07
52 Week High: $6.86
52 Week Low: $1.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.23% -4.99%
12 Week -39.03% -31.48%
Year To Date -56.27% -46.57%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 JUBILEE AVENUE MILTON PARK
-
ABINGDON,X0 OX14 4RX
GBR
ph: 44-12-3543-0000
fax: 44-12-3543-0001
ir@adaptimmune.com http://www.adaptimmune.com
 
 • General Corporate Information   
Officers
Adrian Rawcliffe - Chief Executive Officer and Director
David M. Mott - Chairman
Gavin Wood - Chief Financial Officer
Lawrence M. Alleva - Director
Ali Behbahani - Director

Peer Information
Adaptimmune Therapeutics PLC (CORR.)
Adaptimmune Therapeutics PLC (RSPI)
Adaptimmune Therapeutics PLC (CGXP)
Adaptimmune Therapeutics PLC (BGEN)
Adaptimmune Therapeutics PLC (GTBP)
Adaptimmune Therapeutics PLC (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00653A107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 161.87
Most Recent Split Date: (:1)
Beta: 2.07
Market Capitalization: $265.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.58
Price/Cash Flow: -
Price / Sales: 28.57
EPS Growth
vs. Year Ago Period: -33.33%
vs. Previous Quarter: -28.00%
Sales Growth
vs. Year Ago Period: 723.73%
vs. Previous Quarter: 152.29%
ROE
03/31/22 - -76.84
12/31/21 - -61.15
09/30/21 - -53.31
ROA
03/31/22 - -41.79
12/31/21 - -38.93
09/30/21 - -38.81
Current Ratio
03/31/22 - 5.43
12/31/21 - 6.64
09/30/21 - 7.30
Quick Ratio
03/31/22 - 5.43
12/31/21 - 6.64
09/30/21 - 7.30
Operating Margin
03/31/22 - -1,836.31
12/31/21 - -2,571.00
09/30/21 - -2,499.92
Net Margin
03/31/22 - -1,836.31
12/31/21 - -2,571.00
09/30/21 - -2,499.92
Pre-Tax Margin
03/31/22 - -1,824.17
12/31/21 - -2,558.12
09/30/21 - -2,489.75
Book Value
03/31/22 - 1.04
12/31/21 - 1.32
09/30/21 - 1.54
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©